The journey from the first symptom of a rare disease to a confirmed diagnosis, often referred to as the "diagnostic odyssey," can span years, marked by multiple misdiagnoses and profound patient suffering. While scientific knowledge, particularly in genomics and diagnostics, has advanced exponentially in recent decades, the pharmaceutical industry’s progress in rare disease diagnosis is being significantly hampered by fragmentation. Expertise and crucial data remain siloed across numerous disconnected entities, creating a formidable barrier to timely and accurate identification of these often-debilitating conditions. This pervasive fragmentation, rather than a lack of scientific understanding, is the primary impediment to overcoming the challenges faced by rare disease patients.
This critical issue was a central theme at the 13th European Conference on Rare Diseases and Orphan Products (EURORDIS) held in Prague, Czech Republic, from June 3rd to 4th, 2026. The conference, a pivotal gathering for researchers, clinicians, patient advocacy groups, policymakers, and industry stakeholders, highlighted the urgent need for cohesive strategies to address the multifaceted challenges in rare disease diagnosis and treatment.
The Diagnostic Odyssey: A Global Crisis
The implications of a prolonged diagnostic odyssey are far-reaching. For patients, it means a delay in accessing essential care, including specialized medical support, crucial social services, and potentially life-altering treatments. In Europe, the average wait time from the onset of symptoms to a confirmed diagnosis is a staggering five years, with a disheartening 60% of patients initially receiving incorrect diagnoses. This statistic underscores the systemic failures in current diagnostic pathways.
Dr. Holm Graessner, Managing Director of the Centre for Rare Disease at University Hospital Tübingen, Germany, and a co-chair of the Aspire4Rare Diagnosis Expert Group, presented the Aspire4Rare Diagnosis initiative during one of the conference’s key symposia. This initiative proposes an archetype-based framework designed to untangle the complexity of diagnostic challenges. The framework identifies seven recurring patterns of difficulty: limited awareness among healthcare professionals and inadequate referral pathways; restricted access to essential diagnostic technologies and specialized knowledge; the intricate social context surrounding diagnosis; the inherently dynamic and non-linear nature of rare disease progression; the substantial economic burden on patients and healthcare systems; the lack of standardization in diagnostic protocols; and the crucial role of research in uncovering answers.
The overarching goal of Aspire4Rare Diagnosis is to translate this complexity into recognizable patterns that can be readily understood and addressed by non-specialists, including policymakers and funders who often lack in-depth clinical knowledge. One poignant analogy used at the conference described the diagnostic odyssey as a labyrinth. The accessibility of this labyrinth, and the ability of a patient to even begin navigating it, is heavily influenced by their socioeconomic status and geographical location, with many facing insurmountable barriers before they can even attempt to find their way.
Fragmentation: The Unseen Barrier to Progress
The pharmaceutical industry, despite witnessing a surge in the development of orphan drugs—drugs designed to treat rare diseases—finds its diagnostic efforts stifled by fragmentation. While scientific knowledge has burgeoned, particularly in fields like genomics and advanced diagnostic techniques, the practical application of this knowledge is hampered by its scattered nature. Expertise and data are spread across a multitude of disconnected institutions and databases, creating a significant hurdle for comprehensive diagnosis.
A potential solution lies in the establishment of high-end, networked diagnostic centers. These centers would serve as hubs of expertise, capable of providing comprehensive diagnostic services. The European Reference Networks (ERNs), which are existing collaborations of healthcare providers across Europe, could be further empowered to play a more significant role, rather than being supplanted.
Furthermore, the integration of digital tools needs careful consideration. These tools should not be viewed as a replacement for clinical judgment but rather as intelligent navigators, directing patients to the appropriate specialized centers. The immense volume of rare diseases, estimated to be over 7,000, makes it an impossible task for individual clinicians to retain knowledge of every condition. Therefore, healthcare systems must be designed to bear this informational load, supporting clinicians rather than expecting them to be encyclopedic repositories of rare disease information. The true value of frameworks like Aspire4Rare Diagnosis lies in their ability to establish a shared language and understanding across clinical, social, economic, and political domains. The contemporary challenge is no longer about identifying what needs to be done, but rather about devising effective strategies for implementation.
Revolutionizing Clinical Trials for Rare Diseases
The landscape of rare disease drug development has seen remarkable progress, with the number of approved orphan drugs more than doubling in the past decade. This growth is a testament to advancements in genomics and the development of targeted therapies, which now constitute approximately one-third of the pharmaceutical pipeline. However, the path to bringing these innovative therapies to patients through clinical trials remains fraught with challenges.
Rare diseases, by definition, affect small and geographically dispersed populations. Many are early-onset genetic conditions, making them ill-suited for traditional clinical trial designs. Danielle Dong, ScM CGC, Global Medical Scientific Advocacy Lead for Rare Diseases at Sanofi, addressed these challenges at the EURORDIS conference, discussing the IHI RealiseD initiative.
IHI RealiseD is a significant multi-stakeholder public-private partnership dedicated to enhancing the design and evaluation of clinical trials for rare and ultra-rare diseases. In trials with very small patient cohorts, randomisation, a cornerstone of traditional trial design, may not reliably balance the treatment arms. This can lead to observed differences in outcomes that are attributable to chance rather than the efficacy of the treatment under investigation. Patient heterogeneity further complicates matters. Knowledge about many rare diseases is still limited, leading to the use of trial endpoints derived from related common diseases, which often fail to capture the nuances of rare disease progression or the specific benefits that matter most to patients.
The RealiseD initiative tackles these issues by maximizing the data extracted from each patient through frequent, repeated measurements and the use of multiple endpoints. It employs statistical techniques that adjust for imbalances between trial arms without relying solely on randomization. Crucially, in situations where the use of a placebo is ethically or practically unfeasible, RealiseD explores the creation of synthetic control arms derived from registry data. These synthetic arms aim to model how patients would have progressed in the absence of the investigational treatment, providing a valuable point of comparison.
Navigating Regulatory and Health Technology Assessment Hurdles
Beyond the direct challenges of trial design, rare disease therapies face significant obstacles in regulatory approval and health technology assessment (HTA). Regulatory bodies assess whether a drug’s benefits outweigh its risks, while HTA evaluates its cost-effectiveness relative to existing options. For rare diseases, these assessments are particularly complex due to the scarcity of relevant comparator treatments and the limited availability of robust real-world data.
The RealiseD initiative seeks to foster early and proactive dialogue between drug developers, regulatory agencies, and HTA bodies. The goal is to establish agreed-upon methodologies for trial design and evidence generation before the trials commence, thereby avoiding contentious debates and delays during the later stages of drug development and assessment. This collaborative approach, involving patients, clinicians, regulators, and HTA bodies working together, is essential to collectively address the unique challenges of rare disease therapeutics and ultimately improve patient outcomes. The success of such initiatives hinges on a unified commitment to breaking down silos and fostering a shared vision for rare disease care.
Broader Implications for Healthcare Systems and Research
The fragmentation of expertise and data in rare disease diagnosis has profound implications for healthcare systems worldwide. It not only prolongs patient suffering but also leads to inefficient resource allocation and increased healthcare costs due to repeated diagnostic tests and ineffective treatments. The lack of standardized diagnostic pathways means that patients in different regions or healthcare systems may face vastly different experiences and outcomes.
The current situation necessitates a paradigm shift towards more integrated and collaborative approaches. This includes investing in the development of comprehensive rare disease registries, promoting data sharing initiatives with robust privacy protections, and fostering interdisciplinary research collaborations. The success of initiatives like Aspire4Rare Diagnosis and IHI RealiseD demonstrates a growing recognition of the need for systemic solutions.
Looking ahead, the pharmaceutical industry, in partnership with patient advocacy groups and academic institutions, must prioritize the creation of robust, interconnected ecosystems for rare disease research and diagnosis. This will involve not only technological advancements but also a fundamental rethinking of how knowledge is shared, how expertise is leveraged, and how patients are guided through the complex healthcare landscape. The ultimate goal is to transform the diagnostic odyssey from a perilous journey into a more streamlined and supportive experience, ensuring that every patient has the opportunity to receive a timely and accurate diagnosis, paving the way for appropriate care and improved quality of life. The journey from symptom to solution is long, but with concerted, collaborative effort, the path can be made significantly shorter and more navigable for those affected by rare diseases.
